These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36483043)

  • 1. Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study.
    Zhao J; Chi Y; Hu C; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Li D; Tang P; Gao M; Zheng X
    Front Oncol; 2022; 12():852032. PubMed ID: 36483043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
    Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
    Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
    Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial.
    Chi Y; Zheng X; Zhang Y; Shi F; Cheng Y; Guo Z; Ge M; Qin J; Zhang J; Li Z; Zhou X; Huang R; Chen X; Liu H; Cheng R; Xu Z; Li D; Tang P; Gao M
    Clin Cancer Res; 2023 Oct; 29(20):4047-4056. PubMed ID: 37594724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study.
    Cheng Y; Wang Q; Li K; Shi J; Han B; Wu L; Chen G; He J; Wang J; Qin H; Li X
    Cancer Innov; 2023 Jun; 2(3):181-190. PubMed ID: 38089404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
    Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
    JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
    Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
    Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial.
    Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
    Cancer Med; 2022 Feb; 11(4):1081-1087. PubMed ID: 34939373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
    Zhao Y; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Yamaguchi F; Breadner D; Nagano T; Tanaka F; Husain H; Li K; Han B
    Transl Lung Cancer Res; 2022 May; 11(5):776-785. PubMed ID: 35693290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.
    Liu Y; Cheng Y; Li K; Shi J; Liu Y; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X; Hamaji M; Park HS
    Transl Lung Cancer Res; 2021 Sep; 10(9):3793-3806. PubMed ID: 34733629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
    Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
    Jiang S; Liang H; Liu Z; Zhao S; Liu J; Xie Z; Wang W; Zhang Y; Han B; He J; Liang W
    Oncologist; 2020 May; 25(5):e870-e874. PubMed ID: 32077550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.
    He Z; Liu J; Ma Y; Jiang H; Cui Z; Wang G; Wu Y; Liu J; Cai X; Qian J; Huang J; Zhang H; Li H
    Cancer Manag Res; 2021; 13():6101-6111. PubMed ID: 34377028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
    Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
    Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
    Zhang S; Wang X; Gu H; Liu JQ
    Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
    Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
    Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
    Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
    Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.